Resources

Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.

 

Best Practices for Health and Social Service Providers Working with People Who Use Drugs

Short visual summary of Blood Ties' "Don't Be An A**hole" best practices report
Infographic | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma

Don't Be An A**hole: Best Practices for Health and Social Service Providers Working with People Who Use Drugs

Outlines key themes found among people who use drugs about their experiences with various health and social service agencies and providers in Whitehorse
Report | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma

COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists

Guidelines | 2020
Clinical guidance, About pharmacists, About prescribers

Pharmacists Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies: Notification to all pharmacists in the Vancouver Coastal Health (VCH) region

Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs

Prescriber Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies: Notification to All Prescribers in the Vancouver Coastal Health (VCH) Region

Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs

A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting

Very little is known about the value of UDS, the optimum screening frequency in general, or its specific use for buprenorphine treatment in primary care.
Original research | 2021
Clinical guidance, About prescribers, Outcomes, Substitution/OAT, Diversion

Ketamine for the treatment of acute pain

Guidelines | 2021
Clinical guidance, About prescribers, Chronic pain

Opioid Agonist Treatment (OAT) Guidance During the COVID-19 Pandemic

Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.
Guidelines | 2020
Clinical guidance, Harm reduction, About pharmacists, About prescribers

5 Things You Should Know About Safer Opioid Supply Programs

Commentary | 2021
Clinical guidance, Harm reduction, Hesitancy of prescribers , Safer supply, About pharmacists

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder

Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this in
Original research | 2019
Clinical guidance, Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Substitution/OAT, Injecting drugs

Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction

To raise awareness of alternative techniques that can facilitate buprenorphine-naloxone treatment for opioid use disorder.
Original research | 2020
Clinical guidance, Harm reduction, About prescribers, Substitution/OAT

Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review

Shared decision-making (SDM) is an approach to clinical decision-making that includes patients' values and preferences during health-related decisions.
Scoping review | 2021
Clinical guidance, About prescribers, About PWUD

Stakeholder preferences for supervised consumption site design, staff, and ancillary services: A scoping review of feasibility studies

We conducted a scoping review of feasibility studies reporting on preferred SCS design characteristics, staffing models and ancillary services.
Scoping review | 2021
Overdose, Clinical guidance, About prescribers, About PWUD, Illegal drugs, SCS/OPS

Telehealth-Delivered Opioid Agonist Therapy for the Treatment of Adults with Opioid Use Disorder: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

This Rapid Response report aims to review the effectiveness of the use of telehealth-delivered OAT compared to standard OAT.
Lit review | 2018
Clinical guidance, Evidence base, Policy/Regulatory, Safer supply, About prescribers

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report

Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, and opioid dependence from PST use can develop.
Original research | 2021
Withdrawal, Clinical guidance, Hesitancy of prescribers , About prescribers, Outcomes, Chronic pain, Substitution/OAT, Stigma

Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams

Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.
Guidelines | 2020
Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion

Substance Replacement Therapy in the Context of the COVID-19 Pandemic in Québec: Clinical Guidance for Prescribers

Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs

An introductory guide for assessing and understanding common wounds with people who inject drugs

Guide or handbook | 2020
Clinical guidance, Harm reduction, Illegal drugs, Injecting drugs

The Structure, Growth, and Development of an Addiction Medicine & Rural Service

Slide deck | 2021
Clinical guidance, About prescribers, Small/medium cities

Bioequivalence Following Buccal and Sublingual Placement of Fentanyl Buccal Tablet 400μg in Healthy Subjects

FBT is indicated for the management of breakthrough pain (a transient flare of pain on a background of chronic pain otherwise controlled by treatment with opioids) in patients with cancer who are alre
Original research | 2008
Clinical guidance, About prescribers, Chronic pain

Refine Your Search

Keywords
Format
Region